AACAP Endorses the Inclusion of Methylphenidate in the WHO Model Lists of Essential Medicines.

Cortese, Samuele; Coghill, David; Mattingly, Gregory W; Rohde, Luis Augusto; Thom, Robyn P; Wilens, Timothy E; Wong, Ian C K; Faraone, Stephen V

Cortese, Samuele; Coghill, David; Mattingly, Gregory W; Rohde, Luis Augusto; Thom, Robyn P; Wilens, Timothy E; Wong, Ian C K; Faraone, Stephen V.

Afiliación

Cortese S; Centre for Innovation in Mental Health, School of Psychology, Faculty of Environmental and Life Sciences; Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, United Kingdom; University of Bari "Aldo Moro", Bari, Italy; Solent NHS Trus
Coghill D; University of Melbourne, Melbourne, Australia, and Murdoch Children's research Institute, Melbourne, Australia.
Mattingly GW; Center for Neuroscience, Feinstein Institute for Medical Research, Manhasset, New York, and Midwest Research Group, Washington University School of Medicine, St. Louis, Missouri.
Rohde LA; Attention Deficit/Hyperactivity Program and Developmental Psychiatry Program, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil; Medical Council, UniEduK, São Paulo, Brazil; and the Center for Research and Innovation in Mental Health, National Instit
Thom RP; Lurie Center for Autism, Lexington, Massachusetts; Massachusetts General Hospital, Boston, Massachusetts; and Harvard Medical School, Boston, Massachusetts.
Wilens TE; School of Medicine, Harvard University, Boston, Massachusetts.
Wong ICK; University of Hong Kong Hong Kong SAR China; Centre for Medicines Optimisation Research and Education University College London Hospitals NHS Foundation Trust London United Kingdom; and Aston School of Pharmacy, Aston University, Birmingham, United Kingdom.
Faraone SV; Norton College of Medicine at SUNY Upstate Medical University, Syracuse, New York.

J Am Acad Child Adolesc Psychiatry ; 63(7): 663-665, 2024 Jul.

Article en En | MEDLINE | ID: mdl-38428579

ABSTRACT

ABSTRACT

Despite decades of clinical use and a large body of evidence, the WHO continues to exclude methylphenidate for attention-deficit/hyperactivity disorder (ADHD) from its EML.1 The exclusion of methylphenidate has dire implications for millions of individuals with ADHD worldwide, especially those living in low and low-middle income countries (LMIC), where governmental decisions to make medicines available are contingent on EML listing.

Asunto(s)

Trastorno por Déficit de Atención con Hiperactividad; Estimulantes del Sistema Nervioso Central; Metilfenidato; Organización Mundial de la Salud; Metilfenidato/uso terapéutico; Metilfenidato/farmacología; Humanos; Trastorno por Déficit de Atención con Hiperactividad/tratamiento farmacológico; Estimulantes del Sistema Nervioso Central/farmacología; Estimulantes del Sistema Nervioso Central/uso terapéutico; Medicamentos Esenciales; Niño

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Trastorno por Déficit de Atención con Hiperactividad / Organización Mundial de la Salud / Estimulantes del Sistema Nervioso Central / Metilfenidato Idioma: En Revista: J Am Acad Child Adolesc Psychiatry Asunto de la revista: PEDIATRIA / PSIQUIATRIA Año: 2024 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google